Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03618095 · ClinicalTrials.gov registry record · NA
REPRISE IV: LOTUS Edge Valve System in Intermediate Surgical Risk Subjects
A NA study, sponsored by Boston Scientific Corporation.
- Terminated
- Registry status
- NA
- Development phase
- 382
- Enrollment target
NCT03618095 is a NA study that was terminated before completion, run by Boston Scientific Corporation. The registered enrollment target is 382 participants.
The verdict
NCT03618095, a NA study, was terminated before completion, sponsored by Boston Scientific Corporation.
- TERMINATED
- Registry status
- NA
- Development phase
- 382 participants
- Enrollment target
Study Summary
REPRISE IV: REpositionable Percutaneous Replacement of Stenotic Aortic Valve through Implantation of LOTUS Edge Valve System in IntermediatE Surgical Risk Subjects
Interventions
- DEVICE LOTUS Edge Valve System
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 382 participants |
| Start Date | 2019-01-14 |
| Est. Completion | 2021-03-31 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03618095
The ClinicalTrials.gov registry entry for NCT03618095 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 382 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boston Scientific Corporation, which has 280 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which LOTUS Edge Valve System is the first listed.
NCT03618095 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03618095 about?
NCT03618095 is a clinical study titled "REPRISE IV: LOTUS Edge Valve System in Intermediate Surgical Risk Subjects". REPRISE IV: REpositionable Percutaneous Replacement of Stenotic Aortic Valve through Implantation of LOTUS Edge Valve System in IntermediatE Surgical Risk Subjects
What is the current status of trial NCT03618095?
This trial is currently terminated. It is a NA study. The enrollment target is 382 participants. The study started on 2019-01-14. Estimated completion is 2021-03-31.
What interventions are being tested in trial NCT03618095?
The interventions under investigation include: LOTUS Edge Valve System (DEVICE).
Who is sponsoring clinical trial NCT03618095?
This trial is sponsored by Boston Scientific Corporation, which has 280 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.